Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) ( (HK:0013) ) has issued an update.
HUTCHMED (China) Limited is set to announce its interim financial results for the first half of 2025 on August 7, 2025. The announcement will be accompanied by two webcast presentations for analysts and investors, available in both English and Chinese, to discuss the results and engage in Q&A sessions. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.